This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 ETF Areas of November That Are Up At Least 25%
by Sanghamitra Saha
Back-to-back upbeat vaccine update, stimulus hopes and a divided government have boosted Wall Street in November.
Top ETF of November & Its Best Stocks
by Sweta Killa
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of November with impressive returns of more than 47%.
Small-Caps Beat Bigger Peers Last Week: 5 Top ETFs
by Sanghamitra Saha
The S&P 500, the Dow Jones, the Nasdaq Composite and the Russell 2000 put up a great show last week, with the Russell 2000 -- the small-cap index -- clocking the best performance.
5 Sector ETFs That Beat the Market in November
by Sweta Killa
We have highlighted a few ETFs that have outperformed the market in November and could be better plays if the trend prevails.
4 Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
Last week was upbeat for Wall Street as vaccine hopes strengthened and consumers indulged in holiday shopping.
Should You Buy Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.
Can Small-Cap ETFs Keep Up the Winning Trend in November?
by Sanghamitra Saha
The month of October was downbeat for Wall Street due to election uncertainty, failed stimulus talks, subdued tech earnings and rising coronavirus cases on the global front.
Why Cannabis Stocks & ETFs Are Soaring
by Neena Mishra
Marijuana stocks are rising on hopes of favorable regulatory environment
Cannabis ETFs Hot Ahead of Elections: Here's Why?
by Sweta Killa
With the election just a day away, five states are seeking to legalize marijuana through ballot measures.
Healthcare ETFs: Winners & Losers in the Light of U.S. Election
by Sanghamitra Saha
The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.
Is it Time to Buy Cannabis Stocks & ETFs?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
How Cannabis ETFs Beat S&P 500 Past Month
by Sanghamitra Saha
Cannabis stocks and ETFs jumped last week. Here's why.
Are Marijuana Stocks, ETFs Poised for Upbeat Earnings?
by Sanghamitra Saha
"Essential Business" status tagged with marijuana selling amid lockdowns should have helped cannabis stocks and ETFs in the first quarter.
Are Marijuana Stocks & ETFs Coronavirus-Proof?
by Sanghamitra Saha
Marijuana companies are witnessing robust demand amid the coronavirus outbreak. Time to buy some earlier-battered marijuana stocks and ETFs?
What Do Canopy Earnings Say About Cannabis ETFs?
by Sanghamitra Saha
Solid earnings drive Canopy Growth stock and boost the industry as a result. Is it right time to buy marijuana ETFs?
Sector ETFs at the Midpoint in Q1: Hits & Misses
by Sanghamitra Saha
The year 2020 has so far been marked with Middle East tensions, the coronavirus outbreak and Wall Street rally. These sector ETFs have come across as winners and losers.
Top ETF Areas of Last Week
by Sanghamitra Saha
Inside the ETF areas that were winners last week.
Cannabis ETFs Are Soaring in 2020: Will the Trend Continue?
by Sweta Killa
With a greater legislative push to legalize recreational marijuana, cannabis ETFs are soaring to start the year and are likely to continue doing so.
What's Ahead for Marijuana ETFs After a Dismal Show in 2019?
by Sanghamitra Saha
Marijuana ETFs hit a high in 2018 only to experience a bloodbath in 2019. Let's see what lies in store for the space in 2020.
Best & Worst ETF Areas of Last Week
by Sanghamitra Saha
Inside the ETF gainers and losers of last week.
Top ETF Stories of November
by Sanghamitra Saha
Inside the key ETF events of the month of November.
Cannabis ETFs in Focus on Thanksgiving Weekend
by Sweta Killa
Cannabis spending rises over the Thanksgiving holiday period, especially Green Wednesday as well as on Black Friday.
Marijuana ETFs Bounce Back: Can the Rally Last?
by Sanghamitra Saha
Passing of a legalization bill by a U.S. congressional committee boosted the battered marijuana ETF space lately.
Can Bill Hopes Relieve Earnings-Induced Pain in Pot ETFs?
by Sanghamitra Saha
A wave of disappointing earnings caused a bloodbath in marijuana ETFs last week. However, talks of an end to the federal embargo on marijuana could turn this segment around.
Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
by Sanghamitra Saha
Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.